Aethlon Medical Reports $7.15M Net Loss for FY26, Faces Going Concern Doubt
AEMD sits 32% above its 52-week low of $1.36 on elevated volume (1.8× avg).
Summary
Aethlon Medical reported its fiscal year 2026 financial results from its 10-K, showing a net loss of $7.15 million and diluted EPS of ($10.61) on revenue of ($7.17 million). While the company noted a 46.6% reduction in net loss compared to the prior year, these significant losses for a micro-cap company reinforce the substantial doubt about its ability to continue as a going concern, as highlighted in the 10-K filing. This follows the recent expansion of its At-The-Market offering, indicating an ongoing need for dilutive financing. The company stated it will require additional funding to support its operations.
At the time of this announcement, AEMD was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $1.36 to $27.40. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.